Literature DB >> 6713316

Limitations of long term use of antiparkinson drugs.

M D Yahr.   

Abstract

Effective control of parkinsonian symptoms can be achieved in a substantial number of patients by the judicious use of dopaminergic agents. To a considerable extent these drugs produce optimal therapeutic effects during the first 3-5 years of their use. Subsequently, efficacy diminishes with reemergence of parkinsonian symptoms as well as a number of untoward responses. The nature, frequency and mechanisms underlying the limitations of long term use of presently available anti-parkinson agents are discussed in this presentation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6713316     DOI: 10.1017/s0317167100046394

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  3 in total

1.  Abnormal eye-head coordination in Parkinson's disease patients after administration of levodopa: a possible substrate of levodopa-induced dyskinesia.

Authors:  M Weinrich; R Bhatia
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-07       Impact factor: 10.154

2.  Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.

Authors:  F Boomsma; J D Meerwaldt; A J Man in't Veld; A Hovestadt; M A Schalekamp
Journal:  J Neurol       Date:  1989-05       Impact factor: 4.849

3.  The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.

Authors:  M A Hely; J G Morris; D Rail; W G Reid; D J O'Sullivan; P M Williamson; S Genge; G A Broe
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-03       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.